Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

520
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
520
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

137
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
137
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

507
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
507
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

514
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
514
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

416
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
416
Surface Membrane Barriers01:18

Surface Membrane Barriers

1.3K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting BRD4 in gastric cancer: promoting apoptosis and suppressing tumor progression.

Frontiers in pharmacology·2026
Same author

RPS20 phosphorylation acts as a molecular switch to integrate inflammatory and oxidative stress signals in sepsis.

Life sciences·2026
Same author

Genomic structural equation modelling of 12 cancers identifies a latent pan-cancer susceptibility factor and shared determinants of carcinogenesis.

EBioMedicine·2026
Same author

Integrated Proteomic Profiling of Whole-Cell and Multi-Post-Translational Modifications Unveils Regulatory Networks in Macrophage Inflammatory Responses.

Journal of proteome research·2026
Same author

FOXK1: a multifaceted regulator in metabolic reprogramming and disease progression.

Biology direct·2026
Same author

Overview of clinical trials on deprescribing: A comprehensive analysis of the ClinicalTrials.gov database.

Journal of the American Pharmacists Association : JAPhA·2026

Related Experiment Video

Updated: Aug 27, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

476

Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex

Xiaonan Chen1, Yiqing Zou1, Shuqi Zhang1

  • 1Lab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Acta Pharmaceutica Sinica. B
|September 30, 2022
PubMed
Summary

A novel pharmaceutical vesicle, RHL/Cl-Ch-cal, effectively eradicates Helicobacter pylori by targeting biofilms, activating immune responses, and killing intracellular bacteria, offering a comprehensive therapeutic strategy.

Keywords:
BiofilmsBiofilms eradication tetralogyHelicobacter pyloriImmune evasionIntracellular bacteriaIn vivoLipid raftPharmaceutical preparations

More Related Videos

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.8K
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

3.6K

Related Experiment Videos

Last Updated: Aug 27, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

476
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.8K
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

3.6K

Area of Science:

  • Microbiology
  • Nanotechnology
  • Pharmacology

Background:

  • Helicobacter pylori infection affects over 50% of the global population, posing significant clinical challenges due to its complex in vivo pathological microenvironment.
  • Current therapies face limitations in effectively eradicating H. pylori, necessitating innovative approaches.

Purpose of the Study:

  • To develop and evaluate a novel pharmaceutical vesicle, RHL/Cl-Ch-cal, for enhanced Helicobacter pylori eradication.
  • To investigate the multi-pronged anti-H. pylori mechanisms of RHL/Cl-Ch-cal, including biofilm disruption, immune modulation, and intracellular bacterial killing.

Main Methods:

  • Fabrication of RHL/Cl-Ch-cal vesicles co-loading cholesterol-PEG, calcitriol, and clarithromycin within a rhamnolipid outer layer.
  • Evaluation of RHL/Cl-Ch-cal's mucus penetration, biofilm eradication tetralogy (destruction, killing, inhibition of re-adhesion), host immune activation, and intracellular H. pylori killing capabilities.
  • Assessment of anti-H. pylori efficacy in a standard H. pylori-infected mouse model.

Main Results:

  • RHL/Cl-Ch-cal demonstrated rapid penetration of the gastric mucus layer.
  • The vesicles effectively executed the biofilms eradication tetralogy against H. pylori.
  • RHL/Cl-Ch-cal successfully activated host immune responses and eliminated intracellular H. pylori by restoring lysosomal acidification.
  • Significant anti-H. pylori efficacy was observed in vivo using the mouse model.

Conclusions:

  • RHL/Cl-Ch-cal presents a comprehensive
  • comprehensive attack
  • strategy for H. pylori eradication.
  • The study highlights the potential of RHL/Cl-Ch-cal in overcoming therapeutic challenges associated with H. pylori infections.